Browsing Tag
Yuling Luo
2 posts
What Alamar Biosciences’ (NASDAQ: ALMR) IPO pop says about the next phase of proteomics investing
Alamar Biosciences surged after its upsized IPO. Read what the debut means for proteomics, public markets, and life science tools investors.
Alamar Biosciences and DZNE partner to profile 23,000 samples in landmark neurodegeneration biomarker study
Alamar Biosciences partners with DZNE to deploy its NULISAseq panels in the Rhineland Study, profiling 23,000 plasma samples for aging and dementia biomarker discovery.